Change of microbiology by AECOPD severity during long-term azithromycin... | Download Scientific Diagram
![Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment - ScienceDirect Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0012369218302459-gr1.jpg)
Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment - ScienceDirect
![IJMS | Free Full-Text | Seasonal Azithromycin Use in Paediatric Protracted Bacterial Bronchitis Does Not Promote Antimicrobial Resistance but Does Modulate the Nasopharyngeal Microbiome IJMS | Free Full-Text | Seasonal Azithromycin Use in Paediatric Protracted Bacterial Bronchitis Does Not Promote Antimicrobial Resistance but Does Modulate the Nasopharyngeal Microbiome](https://pub.mdpi-res.com/ijms/ijms-24-16053/article_deploy/html/images/ijms-24-16053-g001-550.jpg?1699357819)
IJMS | Free Full-Text | Seasonal Azithromycin Use in Paediatric Protracted Bacterial Bronchitis Does Not Promote Antimicrobial Resistance but Does Modulate the Nasopharyngeal Microbiome
![Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial - The Lancet Respiratory Medicine Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/fb41bb23-24c6-495a-bcf5-3907ffff765a/gr1_lrg.gif)
Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial - The Lancet Respiratory Medicine
![Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial - eBioMedicine Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial - eBioMedicine](https://www.thelancet.com/cms/asset/3abd10f5-e09b-40c3-b52e-30c2bf02813a/gr1.jpg)
Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial - eBioMedicine
![Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/f516168b-ca27-473e-b972-7e038d69ea88/gr1.gif)
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine
Should azithromycin be used to treat COVID-19? — Nuffield Department of Primary Care Health Sciences, University of Oxford
![Frontiers | Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations Frontiers | Systemic and functional effects of continuous azithromycin treatment in patients with severe chronic obstructive pulmonary disease and frequent exacerbations](https://www.frontiersin.org/files/Articles/1229463/fmed-10-1229463-HTML-r2/image_m/fmed-10-1229463-g001.jpg)